For adults and children with hemophilia B


Number 1 Factor IX Choice bug

IDELVION is the only extended half-life recombinant Factor IX that delivers:

*Zero median annualized spontaneous bleeding rate when dosed at 7 or 14 days in clinical trials. In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month while not requiring dose adjustments or experiencing spontaneous bleeding. The mean dose for patients receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.

Resources for your patients

CSL Behring is committed to providing treatments and support services that make a meaningful difference in the lives of people with bleeding disorders.

Resources are available to help your patients get the treatment they need for hemophilia B, including:

  • Co-pay assistance for up to $12,000 of annual out-of-pocket expenses
  • A free 30-day trial of IDELVION
  • Reimbursement and access support
  • Lapse-in-coverage support with the CSL Behring AssuranceSM program

References: 1. Hemophilia FIX Market Assessment, Third-Party Market Research. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735.

You are now leaving the current website.

Do you want to continue?